NovoCure Limited develops and commercializes Tumor Treating Fields therapy for solid tumors through wearable medical devices including Optune Gio, Optune Lua and Optune Pax. News about NVCR centers on product approvals, reimbursement decisions, launch activity and the use of TTFields in glioblastoma, pancreatic cancer, non-small cell lung cancer and pleural mesothelioma.
Company updates also cover clinical programs such as PANOVA, LUNAR and KEYNOTE studies, quarterly financial results, research and clinical-study spending, and commercialization across the United States, Europe, Japan and other markets where the company has approved products.
Novocure (NVCR) reported third-quarter 2026 revenue of $193 million, up 16% year over year, and raised its full-year financial guidance. Global active patients increased 19% to 5,260 at September 30. Gross margin rose to 77% from 73%. Net loss narrowed to $10.4 million, or $0.09 per share, from $37.3 million, or $0.33 per share. Adjusted EBITDA, an earnings measure excluding specified expenses, reached $15.7 million versus a $3.0 million loss.
Novocure now expects 2026 revenue of $736 million–$743 million, previously $710 million–$725 million, and adjusted EBITDA of $24 million–$34 million, previously $0 million–$15 million. Quarterly revenue included $4.4 million in one-time claims-approval benefits. In October, Japan approved Optune Pax for adults with unresectable locally advanced pancreatic cancer alongside gemcitabine and nab-paclitaxel. Cash, cash equivalents and short-term investments totaled $463.5 million.
Novocure (NVCR) entered a clinical trial collaboration and supply agreement with Verastem Oncology to evaluate a combination treatment for locally advanced pancreatic cancer. The planned trial will combine Tumor Treating Fields (TTFields), a therapy using electric fields, with gemcitabine and nab-paclitaxel chemotherapy and Verastem’s investigational oral KRAS G12D inhibitor, VS-7375.
Novocure plans to evaluate safety and tolerability in approximately 25 patients, with preliminary efficacy assessed through exploratory endpoints. The company expects enrollment to begin in 2027. Novocure will manage and fund clinical trial operations, while Verastem will supply VS-7375. The combination of TTFields therapy with KRAS inhibitors for pancreatic cancer is investigational; this announcement establishes the collaboration and planned study, not clinical results for the combination.
Novocure (NVCR) received Japanese approval for Optune Pax to treat adults with unresectable locally advanced pancreatic cancer alongside chemotherapy. Japan’s Ministry of Health, Labour and Welfare approved its use with gemcitabine and nab-paclitaxel. Optune Pax delivers Tumor Treating Fields, alternating electric fields, through wearable arrays.
Approval was based on Phase 3 PANOVA-3, which compared the device plus those drugs with the drugs alone as first-line treatment. The trial met its primary endpoint, showing statistically significant improvement in median overall survival. No new safety signals were observed, and serious adverse events were comparable between groups. Device-related skin adverse events affected 76.3% of treated participants; most were mild to moderate, while 21 (7.7%) experienced Grade 3 or higher events. Optune Pax received FDA approval in February 2026 and a CE Mark in June 2026.
Novocure (Nasdaq: NVCR) will report third-quarter 2026 financial results on October 29, 2026, before U.S. financial markets open.
Management will host a conference call and webcast at 8:00 a.m. EDT that day to discuss results for the three months ended September 30, 2026. Presentation slides will be available on the investor relations website for at least 14 days following the call.
Novocure (NVCR)/b) will participate in two investor conferences in September 2026 featuring its CEO and CFO in fireside chats and investor meetings.The company joins the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026 at 10:15 a.m. ET, and the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026 at 3:20 p.m. ET. Live audio webcasts and 14‑day replays will be available on Novocure’s investor relations website.
Novocure (NASDAQ: NVCR) reported Q2 2026 net revenues of $183.6 million, up 16% year-over-year, driven by 18% global active patient growth to 5,128 on Tumor Treating Fields therapy. Gross margin rose to 78%, aided by a one-time $4.9 million tariff refund, and Adjusted EBITDA reached $10.8 million. The quarter ended with a net loss of $15.7 million (loss per share $0.13) and cash, cash equivalents and short-term investments of $440.6 million.
Optune Gio active patients increased 11% to 4,636 and Optune Lua patients rose 51% to 207, while Optune Pax reached 285 active U.S. patients and received a CE Mark in the EU for locally advanced pancreatic cancer. According to Novocure, 2026 revenue guidance was raised to $710–$725 million and Adjusted EBITDA guidance to $0–$15 million.
Novocure (NASDAQ: NVCR) will report its second quarter 2026 financial results on July 23, 2026, before U.S. markets open.
Management will host a conference call and webcast at 8:00 a.m. EDT, with slides and a corporate presentation available via the company’s investor relations website.
Novocure (NASDAQ: NVCR) received a CE Mark for Optune Pax for adult patients with locally advanced pancreatic cancer of exocrine origin, used with gemcitabine and nab-paclitaxel.
The Phase 3 PANOVA-3 trial showed statistically significant gains in median overall survival, one-year survival, time to pain progression and several quality-of-life measures, with mostly mild-to-moderate device-related skin adverse events. Novocure plans to launch Optune Pax in Germany soon.
Novocure (NASDAQ: NVCR) reported topline Phase 3 TRIDENT data in newly diagnosed glioblastoma. Starting Tumor Treating Fields (TTFields) at chemoradiation did not significantly improve overall survival versus starting in maintenance (17.7 vs 17.5 months; HR 0.953; p=0.519).
Both arms showed durable 3‑year survival and no new safety signals; early TTFields initiation was feasible. TRIDENT enrolled 981 patients, with balanced baseline characteristics. Results will be presented at the ASTRO 2026 Annual Meeting.
Novocure (NASDAQ: NVCR) reported Q1 2026 results for the quarter ended March 31, 2026: net revenue $174.1M (+12% YoY), gross margin 78%, and net loss $71.1M (EPS -$0.62). Active patients totaled 4,791 globally. Optune Pax received U.S. FDA approval and recorded 169 prescriptions and 83 active U.S. patients in Q1. Novocure updated 2026 guidance to $690M–$710M revenue and Adjusted EBITDA of $(15)M–$0M. Cash and short-term investments were $432.0M. Key upcoming milestones include TRIDENT topline (Q2 2026) and FDA decision on brain metastases (Q4 2026).